Black Diamond Therapeutics logo

Black Diamond Therapeutics share price today

(BDTX)

Black Diamond Therapeutics share price is $2.14 & ₹183.29 as on 1 Jan 2025, 2.30 'hrs' IST

$2.14

-0.01

(-0.47%)

Market is closed - opens 8 PM, 02 Jan 2025

View live Black Diamond Therapeutics share price in Dollar and Rupees. Guide to invest in Black Diamond Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Black Diamond Therapeutics. Get details on the Indian mutual funds that are investing in Black Diamond Therapeutics. Get Analyst recommendations and forecasts along with all the Black Diamond Therapeutics's financials.

Black Diamond Therapeutics share price movements

  • Today's Low: $2.14
    Today's High: $2.24

    Day's Volatility :4.46%

  • 52 Weeks Low: $2.08
    52 Weeks High: $7.66

    52 Weeks Volatility :72.85%

Black Diamond Therapeutics Returns

PeriodBlack Diamond TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
-41.53%
-10.0%
0.0%
6 Months
-52.13%
-4.7%
0.0%
1 Year
-21.9%
-0.9%
0.0%
3 Years
-61.85%
-2.4%
-21.2%

Black Diamond Therapeutics Key Statistics

in dollars & INR

Previous Close
$2.15
Open
$2.19
Today's High
$2.24
Today's Low
$2.14
Market Capitalization
$121.7M
Today's Volume
$408.0K
52 Week High
$7.66
52 Week Low
$2.08
Revenue TTM
$0.0
EBITDA
$-81.0M
Earnings Per Share (EPS)
$-1.33
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-63.09%

How to invest in Black Diamond Therapeutics from India?

It is very easy for Indian residents to invest directly in Black Diamond Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Black Diamond Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Black Diamond Therapeutics or BDTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Black Diamond Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Black Diamond Therapeutics shares which would translate to 0.400 fractional shares of Black Diamond Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Black Diamond Therapeutics, in just a few clicks!

Returns in Black Diamond Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Black Diamond Therapeutics investment value today

Current value as on today

₹80,969

Returns

₹19,031

(-19.03%)

Returns from Black Diamond Therapeutics Stock

₹21,898 (-21.9%)

Dollar Returns

₹2,867 (+2.87%)

Indian investors sentiment towards Black Diamond Therapeutics

3%

Period: Oct 3, 2024 to Jan 1, 2025. Change in 30 Days versus previous period

Search volume for Black Diamond Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 2, 2025. 3% more investors are searching Black Diamond Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Black Diamond Therapeutics

  • T. Rowe Price Investment Management,Inc.

    18.97%

  • Bellevue Group AG

    15.05%

  • Vestal Point Capital LP

    8.89%

  • NEA Management Company, LLC

    7.86%

  • BlackRock Inc

    5.69%

  • Vanguard Group Inc

    4.10%

Analyst Recommendation on Black Diamond Therapeutics

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Black Diamond Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Black Diamond Therapeutics

What analysts predicted

Upside of 577.57%

Current:

$2.14

Target:

$14.50

Insights on Black Diamond Therapeutics

  • Price Movement

    In the last 7 days, BDTX stock has moved down by -7.0%
  • BDTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 20.7% return, outperforming this stock by 47.2%
  • BDTX vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.8% return, outperforming this stock by 98.6%

Black Diamond Therapeutics Technicals Summary

Sell

Neutral

Buy

Black Diamond Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Black Diamond Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Black Diamond Therapeutics
-13.36%
-52.13%
-21.9%
-61.85%
-94.58%
Regeneron Pharmaceuticals, Inc.
-4.97%
-31.12%
-22.37%
13.59%
91.62%
Biontech Se
-1.42%
42.28%
3.53%
-50.85%
155.61%
Alnylam Pharmaceuticals, Inc.
-6.56%
-6.26%
23.43%
35.31%
102.91%
Vertex Pharmaceuticals Incorporated
-11.88%
-15.14%
-1.95%
80.96%
79.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Black Diamond Therapeutics
NA
NA
NA
-1.27
-0.63
-0.33
NA
1.72
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Black Diamond Therapeutics
Buy
$121.7M
-94.58%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
91.62%
17.61
33.61%
Biontech Se
Buy
$27.3B
155.61%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
102.91%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
79.75%
32.84
-4.51%

About Black Diamond Therapeutics

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Organization
Black Diamond Therapeutics
Employees
54
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Industry
Health Technology

Management People of Black Diamond Therapeutics

NameTitle
Dr. Mark A. Velleca M.D., Ph.D.
CEO, President & Chairman
Dr. David M. Epstein Ph.D.
Co-Founder & Director
Dr. Fang Ni Pharm.D.
Advisor
Dr. Sergey Yurasov M.D., Ph.D.
Chief Medical Officer
Dr. Elizabeth Buck Ph.D.
Co-Founder & Chief Scientific Officer
Ms. Erika Jones
Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
Mr. Brent Hatzis-Schoch Esq., J.D.
COO & General Counsel
Ms. Elizabeth L. Montgomery
Chief People Officer
Ms. Melanie Morrison
Chief Development Officer

Important FAQs about investing in Black Diamond Therapeutics from India :

What is Black Diamond Therapeutics share price today?

Black Diamond Therapeutics share price today stands at $2.14, Open: $2.19 ; Previous Close: $2.15 ; High: $2.24 ; Low: $2.14 ; 52 Week High: $7.66 ; 52 Week Low: $2.08. The stock opens at $2.19, after a previous close of $2.15. The stock reached a daily high of $2.24 and a low of $2.14, with a 52-week high of $7.66 and a 52-week low of $2.08.

Can Indians buy Black Diamond Therapeutics shares?

Yes, Indians can invest in the Black Diamond Therapeutics (BDTX) from India.

With INDmoney, you can buy Black Diamond Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Black Diamond Therapeutics at zero transaction cost.

How can I buy Black Diamond Therapeutics shares from India?

It is very easy to buy Black Diamond Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Black Diamond Therapeutics be purchased?

Yes, you can buy fractional shares of Black Diamond Therapeutics with INDmoney app.

What are the documents required to start investing in Black Diamond Therapeutics stocks?

To start investing in Black Diamond Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Black Diamond Therapeutics

Today’s highest price of Black Diamond Therapeutics (BDTX) is $2.24.

Today’s lowest price of Black Diamond Therapeutics (BDTX) is $2.14.

What is today's market capitalisation of Black Diamond Therapeutics

Today's market capitalisation of Black Diamond Therapeutics BDTX is 121.7M

What is the 52 Week High and Low Range of Black Diamond Therapeutics

  • 52 Week High

    $7.66

  • 52 Week Low

    $2.08

What are the historical returns of Black Diamond Therapeutics?

  • 1 Month Returns

    -13.36%

  • 3 Months Returns

    -52.13%

  • 1 Year Returns

    -21.9%

  • 5 Years Returns

    -94.58%

Who is the Chief Executive Officer (CEO) of Black Diamond Therapeutics

Dr. Mark A. Velleca M.D., Ph.D. is the current Chief Executive Officer (CEO) of Black Diamond Therapeutics.